Semler Scientific, Inc. (SMLR) P/E Ratio History
Deep ValueTrading at 4.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2025
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Semler Scientific, Inc. (SMLR) trades at a price-to-earnings ratio of 4.0x, with a stock price of $20.33 and trailing twelve-month earnings per share of $2.92.
The current P/E is 83% below its 5-year average of 23.8x. Over the past five years, SMLR's P/E has ranged from a low of 10.1x to a high of 49.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, SMLR trades at a 82% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 0.18 (P/E divided by 95% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, SMLR trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SMLR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SMLR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SMLR P/E vs Peers
Patient monitoring and wearable diagnostics peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $545M | 11.5Lowest | -Best | +14%Best | |
| $364B | 30.3 | -Best | -15% | |
| $125B | 70.7 | -Best | -62% | |
| $43B | 36.7 | -Best | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SMLR Historical P/E Data (2018–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $30.00 | $2.78 | 10.8x | -63% |
| FY2025 Q2 | Jun 30 2025 | $38.74 | $2.43 | 15.9x | -45% |
| FY2024 Q4 | - | $54.00 | $4.91 | 11.0x | -62% |
| FY2024 Q3 | Sep 30 2024 | $23.55 | $2.05 | 11.5x | -61% |
| FY2024 Q2 | Jun 30 2024 | $34.40 | $2.04 | 16.9x | -42% |
| FY2024 Q1 | Mar 31 2024 | $29.21 | $2.79 | 10.5x | -64% |
| FY2023 Q4 | Dec 31 2023 | $44.29 | $2.64 | 16.8x | -42% |
| FY2023 Q3 | Sep 30 2023 | $25.37 | $2.50 | 10.1x | -65% |
| FY2023 Q2 | Jun 30 2023 | $26.24 | $2.25 | 11.7x | -60% |
| FY2023 Q1 | Mar 31 2023 | $26.80 | $2.01 | 13.3x | -54% |
| FY2022 Q4 | Dec 31 2022 | $33.00 | $1.79 | 18.4x | -37% |
| FY2022 Q3 | Sep 30 2022 | $37.55 | $1.56 | 24.1x | -17% |
| FY2022 Q2 | - | $28.18 | $1.61 | 17.5x | -40% |
| FY2022 Q1 | - | $49.56 | $1.93 | 25.7x | -12% |
| FY2021 Q4 | Dec 31 2021 | $91.65 | $2.12 | 43.2x | +49% |
| FY2021 Q3 | - | $125.03 | $2.76 | 45.3x | +56% |
| FY2021 Q2 | Jun 30 2021 | $111.79 | $2.86 | 39.1x | +34% |
| FY2021 Q1 | Mar 31 2021 | $107.50 | $2.16 | 49.8x | +71% |
| FY2020 Q4 | - | $94.00 | $1.89 | 49.7x | +71% |
| FY2020 Q3 | Sep 30 2020 | $53.39 | $1.50 | 35.6x | +22% |
| FY2020 Q2 | - | $46.00 | $1.85 | 24.9x | -14% |
| FY2020 Q1 | - | $39.90 | $2.04 | 19.6x | -33% |
| FY2019 Q4 | - | $48.00 | $1.94 | 24.7x | -15% |
| FY2019 Q3 | Sep 30 2019 | $42.00 | $1.68 | 25.0x | -14% |
| FY2019 Q2 | Jun 30 2019 | $43.70 | $0.91 | 48.0x | +65% |
| FY2019 Q1 | Mar 31 2019 | $42.77 | $0.78 | 54.8x | +89% |
| FY2018 Q4 | Dec 31 2018 | $34.40 | $0.65 | 52.9x | +82% |
| FY2018 Q3 | Sep 30 2018 | $35.60 | $0.52 | 68.5x | +135% |
| FY2018 Q2 | Jun 30 2018 | $15.45 | $0.32 | 47.9x | +65% |
Average P/E for displayed period: 29.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SMLR — Frequently Asked Questions
Quick answers to the most common questions about buying SMLR stock.
What is SMLR's P/E ratio?
Semler Scientific, Inc. (SMLR) trailing twelve-month P/E ratio is 4.0x, based on TTM diluted EPS of $2.92. The 5-year average P/E is 23.8x and the historical range spans 10.1x to 49.8x.
Is SMLR stock overvalued or undervalued?
SMLR trades at 4.0x P/E, below its 5-year average of 23.8x. At the 0th percentile of its historical range (10.1x–49.8x), the stock is priced at a discount to its own history.
Is SMLR stock expensive?
No, SMLR is not expensive on a historical basis. The current P/E of 4.0x is below the 5-year average of 23.8x and sits at the 0th percentile of its valuation range.
What is SMLR's historical P/E range?
Over the past 5 years, SMLR's P/E ratio has ranged from 10.1x to 49.8x, with a median of 17.5x and an average of 23.8x. The current P/E of 4.0x places the stock at the 0th percentile of this range. Full historical data spans 2018–2025.
How does SMLR's P/E compare to the S&P 500?
SMLR trades at 4.0x P/E versus the S&P 500 median of 24.4x. The 84% discount to the market suggests lower growth expectations or perceived higher risk.
How does SMLR's valuation compare to Healthcare peers?
Semler Scientific, Inc. P/E of 4.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SMLR's PEG ratio?
SMLR PEG ratio is 0.18, based on a P/E of 4.0x and EPS growth of 95.1%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.
What is SMLR's earnings yield?
SMLR earnings yield is 25.23%, the inverse of its 4.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.